Kornimate/medical-research-clean huggingface dataset:
objective measurement methods for autoimmune disease and dry eye syndrome

Conditions: Sjögren's Syndrome; Systemic Lupus Erythematosus; Rheumatoid Arthritis; Systemic Sclerosis; Ankylosing Spondylitis; Dry Eye Syndrome

Summary: to explore the association among tcm pattern, tcm tongue diagnosis and tcm pulse diagnosis for autoimmune disease and dry eye syndrome

objective: to explore the association among tcm pattern, tcm tongue diagnosis and tcm pulse diagnosis for autoimmune disease and dry eye syndrome method: this study wants to establish the objective measurement of autoimmune disease (aid) as sjögren's syndrome (sjs), systemic lupus erythematosus (sle), rheumatoid arthritis (ra), systemic sclerosis (ssc), ankylosing spondylitis (as) for comparing with the dry eye syndrome (des) subjects. and the investigators want to use the objective measurement tools to explore the association of tcm pattern, heart rate variability (hrv), tcm tongue diagnosis and tcm pulse diagnosis among at least 50 each aid group subjects and at least 50 des subjects. expected results: 1. to evaluate the difference among tcm pattern, hrv, tcm tongue diagnosis, tcm pulse diagnosis for the each aid groups. 2. to evaluate the difference among tcm pattern, hrv, tcm tongue diagnosis, tcm pulse diagnosis for the each des groups. 3. to evaluate the difference among tcm pattern, hrv, tcm tongue diagnosis, tcm pulse diagnosis among the aid groups and des group. keyword: autoimmune disease, dry eye syndrome, tcm pattern, tcm tongue diagnosis, tcm pulse diagnosis

Eligibility criteria:
sjögren's syndrome inclusion criteria: * (1) aged between 20 and 75 years * (2) fulfilled the 2002 american-european consensus criteria for ss (aecg) exclusion criteria: na systemic lupus erythematosus inclusion criteria: * (1) aged between 20 and 75 years * (2) fulfilled the 1982 acr revised systemic lupus erythematosus criteria exclusion criteria: na rheumatoid arthritis inclusion criteria: * (1) aged between 20 and 75 years * (2) fulfilled the 2010 acr/eular rheumatoid arthritis classification criteria exclusion criteria: na systemic sclerosis inclusion criteria: * (1) aged between 20 and 75 years * (2) fulfilled the 1980 acr esystemic sclerosis criteria exclusion criteria: na ankylosing spondylitis inclusion criteria: * (1) aged between 20 and 75 years * (2) fulfilled the 1984 ankylosing spondylitis modified new york criteria exclusion criteria: na dry eye syndrome inclusion criteria: * (1) aged between 20 and 75 years * (2) schirmer's test less than 10 mm/5 min

Keywords: sjögren's syndrome systemic lupus erythematosus rheumatoid arthritis systemic sclerosis ankylosing spondylitis dry eye syndrome
randomised controlled study on the use of psychoeducation for bulimia nervosa in young women

Conditions: Bulimia Nervosa

Summary: the purpose of this study is to evaluate the effectivity of guided self-help via internet and bibliotherapy in the treatment of bulimia nervosa (bn) in young women.

eating disorders and especially bulimia nervosa are psychiatric diseases, affecting 2-4% of women. an intervention such as guided self-help via manuals (bibliotherapy) is a well accepted approach and accepted. development of new technologies in recent years allows delivery of psychotherapy via cd-roms and web-based interfaces. these new technologies have not yet been implemented in austria in treating bulimia nervosa (bn) patients. in particular patients will be involved, who would not attend medical care regularly. the aim of our study is therefore to deliver guided self-help via an internet platform (supported by email contacts) for 100 patients with bn and to investigate the practicability and effectivity of this approach as well as compliance of patients in this group. patients will be found and contacted via internet, get specialized medical investigations, medical care and support via emails. as control group 100 patients with bulimia are treated with bibliotherapy only. beside effectivity, predictors of outcome (clinical, comorbidity, indication to change, personality) are investigated. the proposed study is a randomised controlled trial for effectivity and practicability of new technologies in psychiatric treatment research. this is not a psychotherapy study but a study on psychoeducation, an approach which offers new and helpful opportunities for this patient group.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of bulimia nervosa purging-type * bmi \> 18 or age corresponding bmi in patients younger than 18y. * access to internet available exclusion criteria: * severe depression, alcohol- or drug abuse * acute suicidality

Keywords: bulimia nervosa guided self-help psycho-education
safety and pharmacokinetic profile of ckd-581

Conditions: Lymphoma; Multiple Myeloma

Summary: this study is to determine the maximum tolerated dose (mtd), dose limiting toxicity (dlt), safety and pharmacokinetics (pk) profile of a single agent ckd-581 injection in patients with lymphoma failed to standard therapy. the usefulness of the this regimen is evaluated by response rate, progression free survival.

recently, the role of transcriptional repression through epigenetic modulation in carcinogenesis has been clinically validated with several inhibitors of histone deacetylases and dna methyltransferases. it has long been recognized that epigenetic alterations of tumor suppressor genes was one of the contributing factors in carcinogenesis. inhibitors of histone deacetylase (hdac) de-repress genes that subsequently result in growth inhibition, differentiation and apoptosis of cancer cells. ckd-581 is developed for hdac inhibitors. such as to determine the maximum tolerated dose (mtd), dose limiting toxicity (dlt), safety and pharmacokinetics (pk) profile of a single agent ckd-581 injection in patients with lymphoma failed to standard therapy.

Eligibility criteria:
inclusion criteria: * 20 years and older * histologically or cytologically confirmed lymphoma or multiple myeloma that have failed to standard therapy or for which no life prolonging treatment exists * ecog(eastern cooperative oncology) performance status ≤ 2 * life expectancy 12 weeks * hematopoietic: anc(absolute neutrophil count) ≥ 1,500/mm3, platelet count(plt) ≥ 100,000/mm3, hemoglobin ≥ 9.0g/dl * hepatic: total bilirubin \> 1.5×upper limit of normal(except gilbert's syndrome patients), aspartate aminotransferase(ast) \> 3×upper limit of normal, alanine aminotransferase(alt) \> 3×upper limit of normal(ast, alt ≤ 5.0×uln in case of liver metastases) * renal: serum creatinine ≤ 1.5×upper limit of normal * serum calcium ≤ upper limit of normal (if the multiple myeloma only) * signed a written informed consent exclusion criteria: * have symptoms with brain metastases * history of ischemic heart disease(e.g., myocardial infarction, unstable angina pectoris) or clinically significant heart disease such as nyha class iii and iv congestive atrial arrhythmias, within 6 months prior to first dose of study drug * acute infection or blooding tendencies that would preclude study compliance * other psychiatric disorders or other conditions that would preclude study compliance * receiving antitumor therapy(surgery, immunotherapy or chemotherapy) within 4 weeks prior to first dose of study drug(6 weeks for nitrosoureas and mitomycin c, 2 weeks for radiation therapy) * other concurrent antitumor therapy * have cardiac disease by nature * administration history of histone deacetylase inhibitor * history of serious hypersensitivity or allergy * pregnant or nursing, active serum pregnancy test. fertile patients must use effective contraception * participation in a clinical trial within 4 weeks of first dose of study drug
outcome of very old patients admitted for elective major surgery, the effect of frailty

Conditions: Frail Elderly Syndrome; Surgery--Complications

Summary: the aim of the study is to investigate the effect of frailty in patients ≥ 80 years admitted for elective major abdominal surgery.

patients ≥ 80 years admitted for elective major abdominal surgery will be asked to participate in this study where frailty will be scored using the clinical frailty scale and by measuring hand-grip-strength. primary outcome is mortality at 30 days, 90 days and 1 year.

Eligibility criteria:
inclusion criteria: * age 80 years or above * elective abdominal surgery * informed consent exclusion criteria: * age less than 80 years * emergency surgery * palliative surgery ( e.g performing entero-enteroanastomosis to relieve obstruction)
effect of duolac 7s administration on improving symptom in irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: gut microflora-mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (ibs). the purpose of this study is to investigate the efficacy of duolac7s in changing the colonic microflora and improve the symptoms in ibs sufferers. in all, 64 patients with rome iii positive diarrhea type ibs will complete a 6-week multiple centre controlled clinical trial. patients will be randomized to receive either 2 capsules/day duolac7s or 2 capsules/day placebo. ibs symptoms will be monitored and scored according to likert scale. changes in faecal microflora, stool frequency and form, quality of life (qol) scores will be also monitored.


Eligibility criteria:
inclusion criteria: * age: 18\~65 years * diarrhea type irritable bowel syndrome (by rome iii criteria) * no organic bowel disease (by colonoscopy or barium enema) exclusion criteria: * pregnant women or nursing mothers * hypersensitivity to probiotics * congestive heart failure or ischemic heart disease * systolic blood pressure : more than 160 mmhg or diastolic blood pressure: more than 100 mmhg * uncontrolled diabetes mellitus, secondary dyslipidemia, hyperthyroidism, or hypothyroidism * abdominal surgery (exception: appendectomy, hernia surgery) * more than moderate alcohol drinking
evaluation of the multidimensional dyspnea profile (mdp)

Conditions: COPD Exacerbation; CHF; OSA; COPD

Summary: aim of this multicenter prospective cohort study is the evaluation of the multidimensional qualities of dyspnea in a number of diseases using the multidimensional dyspnea profile (banzett et al, erj 2015).

the study sites will examine patients with copd (chronic obstructive pulmonary disease) in state of acute exacerbation and in stable state, patients with congestive heart failure (chf) in state of acute decompensated cardiac insufficiency, and patients newly diagnosed with obstructive sleep apnea (osa) as a control group. in the acute setting of copd and chf, the questionnaire will be given at the day of hospital admission and at the day of discharge. the patients will additionally fill the severe respiratory insufficiency (sri) questionnaire (in copd) or the physical activity questionnaire 50+ (in chf). in stable state of copd, the questionnaires will be given once during a routine control visit at the hospital or the medical practice. in osa, the questionnaire will be given once during the first visit in the sleep laboratory.

Eligibility criteria:
inclusion criteria: * copd patients with acute exacerbation (group i) * chf patients with acute decompensation (group ii) * stable copd patients (group iii) * osa patients with ahi\>15 (group iv) exclusion criteria: * other severe acute diseases that contradict the participation in a clinical trial * simultaneous participation in another clinical trial * not capable of giving consent * language abilities and other disabilities that contradicts the understanding or completing of a clinical questionnaire

Keywords: dyspnoea mdp
allogenic stem cell transplantation (sct) with non-myeloablative conditioning in patients with relapse non-hodgkin's lymphoma (nhl)

Conditions: Non-Hodgkin Lymphoma

Summary: to evaluate the use of ibritumomab tiuxetan (zevalin) as part of the non myeloablative conditioning with melphalan, fludarabine and thiotepa in patients submitted to allogeneic transplantation of haematopoietic stem cells from family donor's peripheral blood.


Eligibility criteria:
inclusion criteria: 1. written informed consent 2. histologically confirmed b-cell lymphoma of the following subtypes: * lbcdl * grade 3b follicular lymphoma * mantle-cell lymphoma * transformed b-cell lymphoma * burkitt lymphoma in patients not eligible for a conventional allogeneic transplant 3. high-risk b-cell cd20+ lymphoma defined by * having attained less than pr after two chemotherapy lines * post-transplantation relapse * presence of disease detected through a metabolic approach (pet/ct or else ct+pet) either before or after autologous transplantation * inability to collect enough stem cells for autologous transplantation 4. stable disease at the time of transplantation 5. age between 18 and 65 6. performance status (ecog) ≤ 2 7. normal and suitable pulmonary function (dlco ≥ 30%) 8. left ventricular ejection fraction (lvef) determined by ventriculography or echocardiogram ≥ 40% 9. normal hepatic and renal function, with creatinine ≤ 2 mg/dl and bi ≤ 1.5 mg/dl, and alkaline phosphatase ≤ 2.5 x unl ; ast, alt ≤ 2.5 x unl (≤ 5 x unl if hepatic infiltration) exclusion criteria: 1. prior treatment with radiopharmaceutical agents 2. hiv-associated lymphoma 3. presence of human anti-mouse antibodies (hama) or anti-chimeric antibodies (haca) 4. patient's inability to follow the protocol 5. hypersensitivity to 90y-itritumomab tiuxetan 6. presence of severe pathologies that preclude chemotherapeutic treatment 7. pregnant women or pregnancy risk due to inappropriate contraceptive measures 8. breastfeeding women

Keywords: allogeneic lymphoma geltamo z-ric
trial of mistent compared to xience in japan

Conditions: Coronary (Artery); Disease

Summary: to compare the mt005 (mistent) with the xience with respect to target lesion failure (tlf) at 12 months in a non-inferiority trial in a "real world" patient population and to confirm that the domestic extrapolation of the dessolve iii study results is valid.

this is a prospective, randomized, 1:1 balanced, controlled, double-blind, multi-center study comparing clinical outcomes at 12 months between mt005 (mistent) and xience in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions.

Eligibility criteria:
inclusion criteria: * male or female patients ≥20 years; * patients who are eligible for percutaneous coronary intervention (pci); * the vessel should have a reference vessel diameter ranging from 2.5 mm to 3.75 mm. all lesions of the patient must comply with the angiographic inclusion criteria and no more than 4 stents per patient are to be implanted. * the patient is judged to be capable of providing voluntary informed consent and has been fully informed of the nature of the study, is willing to comply with all study requirements and will provide written informed consent as approved by the ethics committee of the respective clinical site. exclusion criteria: * known pregnancy or breastfeeding at time of randomization or planned pregnancy for 12 months after the index treatment. women of childbearing potential must have a negative pregnancy test within 7 days of randomization; * known contraindication or hypersensitivity to sirolimus, everolimus, cobalt-chromium, or to medications such as aspirin, heparin, bivalirudin, and all of the following three medications: clopidogrel bisulfate, ticlopidine, prasugrel; * concurrent medical condition with a life expectancy of less than 12 months; * the patient is unwilling/not able to return for outpatient clinic at 1, 6 and 12 months follow-up; * currently participating in another trial and not yet at its primary endpoint;

Keywords: mistent
the effects of different degrees of head-of-bed elevation

Conditions: Surgery; Thyroid; Nursing Caries

Summary: the patient's position is important for ensuring patient comfort and preventing complications after thyroidectomy. this study was carried out to determine the effects of different degrees of head-of-bed elevation on the respiratory pattern and drainage following thyroidectomy and to provide suggestions for evidence-based clinical practice.

thyroidectomy is a safe surgical procedure commonly used for the treatment of benign or malignant tumors, multinodular goiter and graves disease. however, because of the rich vascular structure of the thyroid gland, serious complications including hemorrhage, hematoma and hematoma-related dyspnea can develop after thyroidectomy. the american thyroid association also suggested to keep the patient in a head-up at 45°-fowler's position in the post anesthesia care unit following thyroidectomy to prevent hematoma formation on the incision site by facilitating venous return from the head and neck. the mentioned guideline does not offer any recommendations regarding the position that should be given to the patients at surgical clinic after thyroidectomy. therefore, this study aimed to identify the effects of different degrees of head-of-bed elevation on respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation.

Eligibility criteria:
inclusion criteria: the eligible participants were those * who were not using anticoagulants, * whose coagulation tests were normal, * who had hemovac drains inserted during thyroidectomy, * who had no contraindication to positioning (e.g., heart failure, chronic obstructive pulmonary disease, dyspnea before surgery and respiratory complications in the post-anesthesia care unit), * who could tolerate positioning, and who volunteered to participate and signed the informed consent form exclusion criteria:the participants excluded from the study; * who were using anticoagulants, * whose coagulation tests were abnormal, * who had hemovac drains inserted during thyroidectomy, * hemovac drains removed in the post-anesthesia care unit following thyroidectomy, * who did not tolerate positioning and who refused to participate

Keywords: thyroidectomy head-of-bed elevation supine position respiratory pattern amount of drainage peripheral oxygen saturation
study of ab598 monotherapy and combination therapy in participants with advanced cancers

Conditions: Advanced Cancer; Advanced Malignancies; Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer (GEJ); Head and Neck Squamous Cell Carcinoma (HNSCC); Non-Small Cell Lung Cancer (NSCLC); Ovarian Cancer; Renal Cell Carcinoma (RCC); Triple Negative Breast Cancer (TNBC)

Summary: the primary purpose of this study is to assess the safety and tolerability of ab598 in participants with advanced malignancies.


Eligibility criteria:
key inclusion criteria: * must have at least 1 measurable lesion per response evaluation criteria in solid tumors (recist) guidance * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * prior systemic radiation or whole brain radiation therapy must have been completed at least 4 weeks before investigational product (ip) administration. other palliative radiotherapy must be completed 2 weeks before investigational product administration, if radiation therapy-related aes have resolved to grade ≤ 1. * monotherapy-specific criteria for dose escalation and pd cohorts: * dose escalation: participants may have any pathologically confirmed advanced or metastatic solid tumor for which standard therapy has proven ineffective, intolerable, or is considered inappropriate. * pharmacodynamic cohorts: participants may have any pathologically confirmed advanced or metastatic solid tumors for which standard therapy has proven ineffective, intolerable, or is considered inappropriate. participants must be able to undergo collection of a fresh frozen biopsy during screening, as well as provide an on-treatment fresh frozen biopsy. * dose expansion cohort criteria: * histologically confirmed, documented diagnosis of her2-negative locally advanced unresectable or metastatic gastric or gej adenocarcinoma. * no prior systemic treatment for locally advanced unresectable or metastatic disease. * cannot have progressed within 6 months of prior platinum-based chemotherapy for earlier stage disease. key exclusion criteria: * use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of study * underlying medical conditions or aes that, in the investigator or sponsor's opinion, will make the administration of the study drugs hazardous * any active or documented history of autoimmune disease including but not limited to inflammatory bowel disease, celiac disease, wegner syndrome, hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of study treatment * history of trauma or major surgery within 28 days prior to the first dose of study drug * treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressant medication during study treatment with certain protocol specified exceptions note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: ab598 ab122 zimberelimab
microsurgical instruments and magnification may enhance treatment outcomes of laterally moved, coronally advanced flap in miller class iii isolated recession defects

Conditions: Gingival Recession, Mucogingival Surgery

Summary: the benefits of microsurgical approaches in periodontal therapy have been described. the main focus of this study is to determine if using microsurgical lmcaf technique would improve the outcomes of the therapy for the miller class iii isolated recession-type defects. six months results of this study showed that lmcaf with microsurgical approach offered better complete and mean root coverage results over macrosurgical lmcaf technique. the superior effect of microsurgical approach on post-operative morbidity can make this technique more preferable for the patients who expected comfortable postoperative period. this study supports that using the microsurgical aproach with lmcaf procedure significantly affects the clinical and patient-centered success of treating miller class iii isolated typed defects.


Eligibility criteria:
inclusion criteria: * presence of miller class iii isolated gingival recessions located at upper and lower incisors and canines (miller 1985) * presence of identifiable cementoenamel junction (cej) * presence of a step ≤ 2mm at cej level and/or the presence of a root abrasion, but with an identifiable cej * lateral keratinized tissue width at least 6 mm greater than the width of the recession measured at the level of the cemento-enamel junction (cej) * lateral keratinized tissue height at least 2 mm greater than the buccal probing depth of the adjacent tooth/teeth * full-mouth plaque score and full-mouth bleeding score of \< 15% (four sites/tooth) -no occlusal interferences; all patients were nonsmokers exclusion criteria: * tooth with a prosthetic crown or restoration involving cej * patients with a history of destructive periodontal disease (o zaman class 3 nasıl oluştu demiş adam) or repeated abscess formation * presence of systemic disease or taking medications known to interfere with periodontal tissue health or healing (patients with insulin-dependent diabetes * history of malignancy, radiotherapy, or chemotherapy for malignancy * disease affecting connective tissue metabolism) * patient pregnant or nursing during the past 5 months * patients who participated in a clinical trial within the past 6 months